Track Krystal Biotech, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Krystal Biotech, Inc. KRYS Open Krystal Biotech, Inc. in new tab

291.75 USD
P/E
39.06
EPS
7.47
P/B
6.98
ROE
19.90
Beta
0.50
Target Price
322.78 USD
Krystal Biotech, Inc. logo

Krystal Biotech, Inc.

🧾 Earnings Recap – Q3 2025

Krystal Biotech delivered a strong Q3 2025, with VYJUVEK revenues reaching $97.8 million, bolstered by recent expansions in Europe and Japan. The company is well-positioned for sustained growth with an expanding prescriber base and new clinical programs underway.

  • VYJUVEK revenues total $97.8 million for Q3, contributing to over $623 million since the product’s launch.
  • Gross margins remained robust at 96%, with an acceleration in over 40 new reimbursement approvals in the U.S. since the last earnings call.
  • Successful launches of VYJUVEK in Germany, France, and Japan are set to enhance patient access and treatment availability.
  • The updated U.S. label for VYJUVEK now includes patients from birth, optimizing the product's market position and potential for higher compliance.
  • Initiation of a new clinical program for Hailey-Hailey disease reinforces Krystal’s commitment to rare disease treatments and expands their innovative pipeline.
📅
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
Earnings dateAug. 3, 2026
P/E39.06
EPS7.47
Book Value41.78
Price to Book6.98
Debt/Equity0.71
% Insiders11.141%
Growth
Revenue Growth0.32%
Earnings Growth0.53%
Estimates
Forward P/E28.94
Forward EPS10.08
Target Mean Price322.78

DCF Valuation

Tweak assumptions to recompute fair value for Krystal Biotech, Inc. (KRYS)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Krystal Biotech, Inc. Logo Krystal Biotech, Inc. Analysis (KRYS)

United States Health Care Official Website Stock

Is Krystal Biotech, Inc. a good investment? Krystal Biotech, Inc. (KRYS) is currently trading at 291.75 USD. Market analysts have a consensus price target of 322.78 USD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 39.06. This high multiple suggests investors have priced in significant future growth expectations.

Earnings Schedule: Krystal Biotech, Inc. is expected to release its next earnings report on Aug. 3, 2026. The market consensus estimate for Forward EPS is 10.08.

Investor FAQ

Does Krystal Biotech, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Krystal Biotech, Inc.?

Krystal Biotech, Inc. is classified as a Stock. You can compare it against 3 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be Aug. 3, 2026. The company currently has a trailing EPS of 7.47.

Company Profile

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Exchange Ticker
NMS (United States) KRYS
FRA (Germany) 4KB.F
STU (Germany) 4KB.SG

Dividends

Historical Split Corporate Actions

Trades
Trade History
No trades yet
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion